The Food and Drug Administration on Nov. 6 awarded six companies vouchers that will accelerate the review process for their products.
“National priority vouchers are granted to a select group of products where the company has agreed to increase affordability, domesticate manufacturing as a national security issue, or address an unmet public health need,” Dr. Marty Makary, the FDA’s commissioner, said in a statement. “We are pioneering new ways of bringing these cures and meaningful treatments to the market faster.”
Regular drug reviews can take about a year. Under the pilot program, companies that receive vouchers are promised to receive decisions on applications within months, provided certain criteria are met….